UCSD Researchers Find FAK Protein Linked to Chemotherapy Resistance in Ovarian Cancer

September 12, 2019 5:00 pm

Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. 

A new study in Read more

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?

August 26, 2019 7:00 pm

By Dave Levitan

The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more

AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study

August 13, 2019 5:15 am

By John Lauerman

AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.

Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more

Ovarian Cancer: Is this the Beginning of the End?

August 10, 2019 6:00 pm

By Michael J. Birrer, MD, PhD

There will be 22,530 new cases of ovarian cancer in the United States this year.

Although tumors often present at an advanced stage, it remains one of the most chemosensitive epithelial cancers, with a … Read more

Discovery of New “Don’t Eat Me Protein” Points the Way to Effective Cancer Therapy

August 1, 2019 4:00 pm

By Alexandru Micu

Stanford University (SU) researchers have found a new signaling molecule that cancer cells use to keep the immune system at bay.

Our bodies’ immune cells are, among other objectives, tasked with clearing out malfunctioning cells. In theory, … Read more

New Discovery Could Open Up PARP Inhibitors to More Cancer Patients

July 25, 2019 4:00 pm

By Amirah Al Idrus

PARP inhibitors have transformed treatment for breast and ovarian cancers, but their use has been limited to the small proportion of patients who have BRCA mutations. New research out of UT Southwestern Medical Center has uncovered … Read more

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer

July 23, 2019 5:00 pm

By Dave Levitan

A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.

“Up to … Read more

Targeting a Key Protein May Keep Ovarian Cancer Cells from Spreading

July 15, 2019 12:50 pm

By Zachary Sweger

Preventing a protein from doing its job may keep a certain type of ovarian cancer cell from growing and dividing uncontrollably in the lab, according to a new study from Penn State College of Medicine.

In … Read more

New Program Helps Patients with Advanced Cancer Access Experimental Drugs

July 11, 2019 7:00 pm

By Jack Elliot

In June 2019, the FDA announced a new program called “Project Facilitate” that is designed exclusively for patients with advanced cancer who have exhausted all available treatment options and are unable to participate in clinical trials. Through Read more

The Need for Clinical Trial Navigators

June 20, 2019 5:00 pm

Our Clinical Trial Finder is a personalized and online search tool that will help you to find a clinical trial based on your location or clinical situation (i.e. platinum sensitive or platinum resistant, number of previous treatments). We can also Read more

Novel Treatment Turns Tumors Into ‘Cancer Vaccine Factories’

June 13, 2019 5:00 pm

By Mark L. Fuerst

In-situ vaccine may enhance immunotherapy response in resistant cancers, study shows.

A novel approach to cancer immunotherapy injects immune stimulants directly into a tumor to “teach,” induce the immune system to destroy the cancer and other

Read more

Trial Examines Tolerance of Maintenance Olaparib in Advanced Ovarian Cancer

June 12, 2019 5:00 pm

By Dave Levitan

An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more

Does Maintenance Rucaparib Improve Post-Progression Outcomes in Ovarian Cancer?

June 10, 2019 7:00 pm

By Dave Levitan

Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more

SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer

June 5, 2019 8:00 pm

By Leah Lawrence

Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more

Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer

June 5, 2019 7:00 pm

By Leah Lawrence

Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more

Scientists Uncover Mechanism of Action for Promising Cancer Compound

June 5, 2019 5:00 pm

University of North Carolina Lineberger Comprehensive Cancer Center researchers have uncovered the mechanism that explains how an investigational cancer therapeutic might be working—a finding that they believe could be important for the design of potential new therapies.

In the journal … Read more

Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer

June 4, 2019 6:00 pm

By Ian Ingram

Benefit seen across all subgroups for patients with platinum-sensitive disease.

Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more

Medicaid Expansion Narrows Racial Gaps in Access to Timely Ovarian Cancer Care

June 4, 2019 5:00 pm

by Paige Minemyer

Medicaid expansion may have significantly reduced racial disparities in access to earlier ovarian cancer treatment, according to a new study.

The findings, which were presented at the American Society of Clinical Oncology’s annual meeting, show that … Read more

ACA May Impact Ovarian Cancer Outcomes

June 2, 2019 5:00 pm

By John Schieszer

Under the Affordable Care Act (ACA), women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis, according to researchers at Johns Hopkins School of Medicine, … Read more

Choosing Sides: Treatment Decisions for Recurrent Ovarian Cancer Must Consider Side Effects

May 30, 2019 6:00 pm

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.

Luckily, doctors have a variety of ways to relieve or prevent these discomforts.

Read more